Intellipharmaceutics International Inc. (IPCI)

[numbersarefun]

AngeloFoca, Glucophage_XR not partnered with Mallinckrodt. IPCI's four generics with low price per pill are not partnered yet. Mallinckrodt picked the three generics left with high price per pill. I would guess to capture 1% of Glucophage, IPCI would have to sell millions of pills at a very low price. IPCI probably could not handle that large of a manufacturing job at its site.

AngeloFoca wrote: "my mistake... Glucophage's XR market is $2.4 Billion.

Assuming a 50-50 split with Mallinckrodt... every 1% of the market that IPCI/MNK capture will be $24 million... or $12 million to IPCI's bottom line... assuming 2.5% penetration IPCI's pure profit would be $30 million a year. "